ArticlebioRxiv : the preprint server for biology2025
Whole blood transcriptional signatures of age and survival identified in Long Life Family and Integrative Longevity Omics Studies.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
21 authors.
Funding
Abstract
Background: Age is one of the major risk factors for a wide range of diseases. Nevertheless, some individuals can better cope with these changes and become centenarians. We hypothesize that their blood transcriptome may provide insights into the mechanisms contributing to healthy aging, as well as enable the discovery of candidate therapeutic targets. The Long-Life Family Study (LLFS), which includes participants from families enriched with long-lived individuals, serves as a valuable dataset for achieving these objectives. Methods: To identify transcripts associated with age, we analyzed the association between age at blood draw and 16,284 RNAseq-based blood transcriptomic data from 2,167 LLFS participants with ages ranging from 18 to 107. We used linear mixed-effect models controlling for familial relatedness and adjusted for genetic, socioeconomic, and technical confounders. We validated results in a dataset of 20,884 RNAseq-based blood transcriptomic data from 434 participants of the Integrative Longevity Omics Study, and compared findings to a published reference aging signature. We integrated the results by building a transcriptomic aging clock. We also identified transcripts associated with mortality risk using a Cox-proportional hazard model. Results: We identified 4,227 transcripts increasing and 4,044 transcripts decreasing with age. Age-associated expression patterns were significantly replicated in external datasets, with high correlation (R = 0.78 - 0.94). Enrichment analysis revealed age-related upregulation of inflammatory and senescence-related pathways (e.g., IFN-γ response, TNF-α/NF-κB signaling), and downregulation of MYC and Wnt/β-catenin targets, among others. WGCNA identified co-expression modules reflecting inflammation, immune signaling, and decreased protein synthesis. We also identified 314 transcripts significantly associated with mortality risk and found that pro-survival gene sets included NK cell-mediated cytotoxicity and GPCR signaling. A subset of transcripts showed age associations unique to longevity-enriched cohorts and not present in non-longevity populations, implicating IL6-Jak-Stat3, mitotic spindle, and p53 pathways. Finally, transcriptomic age (delta-age) was strongly associated with increased mortality (HR = 1.108, p = 3.33e-18), with significant survival differences between delta-age groups. Conclusions: This study identified robust transcriptomic signatures of aging and mortality in a longevity-enriched population, highlighting key biological pathways such as immune modulation, inflammation, and senescence. Age-associated expression profiles that are unique to long-lived individuals may represent resilience mechanisms distinct from general aging trends. Transcriptomic age acceleration is a strong predictor of mortality, reinforcing its utility as a molecular biomarker of biological aging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.